Product
SARS-CoV-2 rS/Matrix M1-Adjuvant
1 clinical trial
1 indication
Indication
COVID-19Clinical trial
A Phase 3, Randomised, Observer-Blinded, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1™ Adjuvant in Adult Participants 18-84 Years of Age in the United KingdomStatus: Completed, Estimated PCD: 2022-03-29